Norstella-wide data and insights power evidence-based portfolio decisions.
Modular offerings scale to client needs, scope, and budget.
Decades of experience guiding portfolio strategy across asset sizes.
Integrated qualitative and quantitative methods drive confident investment decisions.
Our team can provide insights to enable informed portfolio strategy decisions.
We help with:
Market sizing and forecasting
Commercial opportunity assessment
Indication prioritization and strategy
Portfolio optimization
Whether you need to size opportunies, prioritize indications, or support business development and investor discussions, partner with our consultants for credible forecasts and valuations that stand up to scrutiny
What is the realistic market positioning and uptake potential for the asset?
What is the commercial value and NPV across different scenarios and TPPs?
How do KOLs and payers view unmet need, treatment patterns, and future competitive dynamics?
How can we credibly defend and maximize asset value in investor or partner discussions?
Whether you need to validate a new target, understand a competitive landscape, or pressure‑test early strategy, our consultants help you cut through complexity, ground decisions in market reality, and focus your portfolio where it can really win. Connect with us to strengthen early strategy, support go/no‑go decisions, and move forward with confidence
Is this indication, target, or MoA worth pursuing?
Where is the true unmet need, and how competitive is the landscape?
Which indications make most biological or mechanistic sense?
How do KOLs assess opportunity, feasibility, and development risk?
Which markets best align with our portfolio strategy?
What risks or blind spots emerge from an independent view?
Whether you need to validate an emerging trend, understand where capital and innovation are moving, or ensure your portfolio strategy stays ahead of market change, we can support you. Our consultants help you turn complex trend signals into clear, actionable direction. Connect with us to keep your strategy aligned with market direction.
What do investment, deal, or development trends look like in this space?
Where is activity most concentrated, and how is it shifting over time?
Which trends should we anticipate and act on ahead of competitors?
Where should we focus portfolio, investment, or strategic effort, and where should we avoid?
Who are the key players shaping the trend today and tomorrow?
What risks or opportunities might we miss without an independent view?
Whether you are prioritizing 10 or 20 potential indications, we deliver objective, data‑driven clarity on where your asset can win. Partner with Evaluate Advisory to build a defensible indication strategy that aligns clinical promise with commercial value.
Which indications are most attractive for our asset, based on data not opinion?
How can we clearly defend our indication and portfolio strategy with evidence?
Which high‑potential indications might we be overlooking?
Whether you need to pressure‑test a TPP, prioritize indications, or strengthen clinical and commercial strategy ahead of key decisions, partner with Evaluate Advisory to turn evidence into clear, actionable direction.
Where can our TPP win, and which indications merit progression?
How do KOLs view unmet need, current treatment, and future competitive shifts?
Does the TPP deliver clinically meaningful differentiation to drive adoption?
What level of benefit is required to displace standard of care?
How do payers assess value, access risk, and reimbursement potential?
Every strategic challenge is different. If you need to answer a unique commercial question or require tailored support beyond standard solutions, our consulting team will work with you to design an approach that fits your objectives, timelines, and data needs.
Hear directly from our consulting experts on how we work with clients, approach complex challenges, and deliver insight‑led support across the commercial lifecycle.
Our experts will help you identify the tools and insights that support your strategic, commercial, or investment priorities.
Paul leads the Evaluate’s consulting and analytics business, overseeing strategic advisory engagements across portfolio strategy, asset strategy, competitive intelligence, forecasting, valuation, and BD&L, working with clients across the global pharma and biotech ecosystem.
Paul brings extensive experience spanning academic research and life sciences consulting, supporting organizations ranging from early-stage biotech companies to large pharmaceutical corporate strategy teams. His work focuses on helping clients make evidence-based decisions across the product lifecycle, from pipeline prioritization through to commercial strategy and investment decision-making.
Mark leads client engagements focused on asset strategy, portfolio prioritization, opportunity assessment, forecasting and valuation, and development strategy across pharma and biotech portfolios. Mark brings over 25 years of biopharma and life sciences experience, having worked across academia, large pharma, and consulting roles. His background includes hands-on experience as a medicinal chemist, followed by senior analytical and advisory positions supporting strategic decision-making in R&D and commercial planning.
Get in touch with our team to explore the right solutions for your business.
